Original Research
Published on 30 Apr 2020
Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype
in Women's Cancer
Frontiers in Oncology
doi 10.3389/fonc.2020.00547
- 4,857 views
- 19 citations
